A Clinical Trial of Haptenized Autologous Cell Vaccine (BVX 0918A) in Combination with Anti-PD1 and Anti-PDL-1 Checkpoint Inhibitors
Latest Information Update: 29 Dec 2020
At a glance
- Drugs BVX-0918A (Primary) ; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors BioVaxys
- 29 Dec 2020 New trial record
- 21 Dec 2020 According to a BioVaxys media release, planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer.